Tuesday, 25 Jul 2017

You are here

lxekizumab Performance in TNF Nonresponders Phase 3 Trial

Ixekizumab performs well in TNF nonresponders phase 3 trial.

With more IL17 inhibitors becoming available for treatment of seronegative spondyloarthropathies the question of efficacy and safety in different clinical scenarios arises.

The phase 3 PsA SPIRIT-P2 trial involving 363 patients with PsA who failed or could not tolerate 1-2 TNFi randomized patients into 3 groups: PBO, IXE 80 mg q 2 weeks and IXE 80 mg q 4 weeks.

Acr 20 was assessed in 24 weeks as a primary end point. 16 week escape was allowed.

 

 

Best response was observed in arthritis and dactylitis domain in both IXE groups with ACR20 65 [53.3%], 59 [48%] vs. 23 [19.5%]; Q4W, Q2W, placebo, respectively. At the same, rates of enthesitis resolution were not significantly different compared to placebo. 

 

In terms of safety, serious AE and oral candidiasis were numerically higher with Q2W vs placebo. No deaths or cases of inflammatory bowel disease, uveitis, TB reactivation, or grade ≥3 neutropenia were reported.

The study concluded that IXE improves arthritis, skin psoriasis and physical function with no unexpected safety findings in patients with active PsA and prior IR or intolerance to TNF-inhibitor(s).

The safety profile of IXE was comparable to safety findings from SPIRIT-P1 trial.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

The RheumNow Week in Review – 21 July 2017

Dr. Jack Cush reviews the news from the past week on RheumNow.com: 

The RheumNow Week in Review – 14 July 2017

Dr. Jack Cush reviews highlights from the past week on RheumNow.com:

Pharma Pays $8.2 Billion to Physicians in 2016

Data made public by the Centers for Medicare & Medicaid Services shows that drug and device makers made nearly $8.2 billion in payments to U.S. physicians and teaching hospitals in the last year. Since 2013, CMS has been tracking physician payments as part of the Affordable Care Act.

The RheumNow Week in Review – 30 June 2017

Dr. Jack Cush reviews highlights from the past week on RheumNow.com:

ACR Says Senate Healthcare Bill Falls Short of Protecting Americans with Rheumatic Disease

Dr. Sharad Lakhanpal, President of the American College of Rheumatology has responded to the Senate's proposed changes to healthcare coverage in the USA.